
Myeloproliferative Neoplasm (MPN) Reflex Panel With BCR-ABL







The Myeloproliferative Neoplasm (MPN) Reflex Panel With BCR-ABL is a comprehensive genetic test that identifies key mutations linked to blood cancers known as myeloproliferative neoplasms (MPNs). It helps detect and differentiate chronic myeloid leukemia (CML) from other MPNs, guiding accurate diagnosis, treatment decisions, and disease monitoring.








Understanding Myeloproliferative Neoplasm (MPN) Reflex Panel With BCR-ABL
Chronic myeloproliferative neoplasms (MPNs) are a group of blood disorders where the bone marrow produces too many red blood cells, white blood cells, or platelets. This uncontrolled cell growth can lead to complications such as blood clots, bleeding problems, or progression to acute leukemia.
The Myeloproliferative Neoplasm (MPN) Reflex Panel With BCR-ABL combines next-generation sequencing (NGS) with reflex testing to identify mutations in the BCR-ABL1, JAK2, MPL, and CALR genes. All of these genes play a vital role in the diagnosis and classification of MPNs.
This test works in a stepwise or “reflex” manner. It first screens for the BCR-ABL1 fusion gene, the hallmark of chronic myeloid leukemia (CML). If BCR-ABL1 is negative, the test reflexively analyzes other MPN-related genes known as JAK2 (including the common V617F and exon 12–15 mutations), followed by MPL and CALR if needed.
By examining these genetic regions sequentially, the test distinguishes CML (BCR-ABL–positive) from BCR-ABL–negative MPNs, such as polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). This comprehensive approach ensures an accurate molecular diagnosis, supports personalized treatment planning, and helps doctors monitor disease progression and treatment response effectively.
Doctors may recommend this panel if you experience symptoms such as fatigue, weakness, night sweats, or an enlarged spleen, or if you have abnormal blood counts. It is also advised for individuals with a family history of MPNs or known genetic risk factors. This test helps diagnose specific MPNs, differentiate between subtypes for appropriate treatment, monitor therapy response, and assess complication risks.
For this test, it is important to submit the clinical history, histopathology report, previous test results, and a doctor’s prescription at the time of sample collection. The Tata 1mg consolidated Test Requisition Form (TRF) must also be duly filled and submitted.
Lab test results may vary across different laboratories. Abnormal test results require an expert interpretation. Therefore, never try to self-medicate at home based solely on these results, and always consult a doctor for proper understanding of the test results.
Note: Genetic counseling can be provided. If interested, please send the request to this email id: [email protected]
What does Myeloproliferative Neoplasm (MPN) Reflex Panel With BCR-ABL measure?
The Myeloproliferative Neoplasm (MPN) Reflex Panel With BCR-ABL measures specific genetic mutations that drive abnormal blood cell production. It detects the BCR-ABL1 fusion gene, which confirms chronic myeloid leukemia (CML), and reflexively analyzes JAK2, CALR, and MPL mutations to identify BCR-ABL–negative MPNs such as polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF).
By combining these analyses, the test provides a complete molecular picture of the disease, helping doctors confirm the exact MPN subtype, predict disease behavior, and plan safe and effective treatment strategies. Abnormal results indicate the presence of genetic mutations responsible for uncontrolled blood cell production, guiding doctors in making precise and personalized therapeutic decisions.





FAQs related to Myeloproliferative Neoplasm (MPN) Reflex Panel With BCR-ABL
- Rapado I, Grande S, Albizua E, Ayala R, Hernández JA, Gallardo M, Gilsanz F, Martinez-Lopez J. High resolution melting analysis for JAK2 Exon 14 and Exon 12 mutations: a diagnostic tool for myeloproliferative neoplasms. J Mol Diagn. 2009 Mar;11(2):155-61. [Accessed 16 Oct. 2025]. Available from:
- Thapa B, Fazal S, Parsi M, et al. Myeloproliferative Neoplasms. [Updated 2023 Aug 8]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from:
- Stock W, Yu D, Karrison T, Sher D, Stone RM, Larson RA, Bloomfield CD. Quantitative real-time RT-PCR monitoring of BCR-ABL in chronic myelogenous leukemia shows lack of agreement in blood and bone marrow samples. Int J Oncol. 2006 May;28(5):1099-103. PMID: 16596225. [Accessed 16 Oct. 2025]. Available From:
Other tests
- CBC (Complete Blood Count)
- FBS (Fasting Blood Sugar)
- Thyroid Profile Total (T3, T4 & TSH)
- HbA1c (Glycosylated Hemoglobin)
- PPBS (Postprandial Blood Sugar)
- Lipid Profile
- Vitamin D (25-Hydroxy)
- Urine R/M (Urine Routine & Microscopy)
- Coronavirus Covid -19 test- RT PCR
- LFT (Liver Function Test)
- KFT (Kidney Function Test)
- TSH (Thyroid Stimulating Hormone) Ultrasensitive
- ESR (Erythrocyte Sedimentation Rate)
- Uric Acid, Serum
- Vitamin B12
- CRP (C-Reactive Protein), Quantitative
- Urine C/S (Urine Culture and Sensitivity)
- Serum Electrolytes
- Serum Calcium
- Serum Creatinine
- Diabetes Screening (HbA1C & Fasting Sugar)
- KFT with Electrolytes (Kidney Function Test with Electrolytes)
- Cholesterol - Total
- Hb (Hemoglobin)
- Complete Hemogram (CBC & ESR)





